日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The feasibility of circulating tumor DNA analysis as a marker of recurrence in triple-negative breast cancer

循环肿瘤 DNA 分析作为三阴性乳腺癌复发标志物的可行性

Satoshi Okazaki, Takaaki Sasaki, Shunsuke Yasuda, Masahiro Abe, Nana Yoshida, Ryohei Yoshida, Kei Ishibashi, Yoshinori Minami, Shunsuke Okumura, Shinichi Chiba, Hidehiro Takei, Ryusuke Hayashi, Toshihiro Nagato, Hiroya Kobayashi, Ayumu Sugitani, Yusuke Ono, Yusuke Mizukami, Masahiro Kitada, Yoshinob

Novel ALK-specific mRNA in situ hybridization assay for non-small-cell lung carcinoma

针对非小细胞肺癌的新型 ALK 特异性 mRNA 原位杂交检测方法

Noriko Hirai, Takaaki Sasaki, Shunsuke Okumura, Masatoshi Sado, Naoko Akiyama, Masahiro Kitada, Hidehiro Takei, Yoshinobu Ohsaki

PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma

PD-L1 特异性辅助 T 细胞表现出有效的抗肿瘤反应:针对头颈部鳞状细胞癌 PD-L1 的癌症免疫治疗新策略

Yui Hirata-Nozaki, Takayuki Ohkuri, Kenzo Ohara, Takumi Kumai, Marino Nagata, Shohei Harabuchi, Akemi Kosaka, Toshihiro Nagato, Kei Ishibashi, Kensuke Oikawa, Naoko Aoki, Mizuho Ohara, Yasuaki Harabuchi, Yuji Uno, Hidehiro Takei, Esteban Celis, Hiroya Kobayashi

Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy

程序性死亡配体 1 及其可溶性形式在鼻腔自然杀伤细胞/T 细胞淋巴瘤中高度表达:免疫治疗的潜在原理

Toshihiro Nagato, Takayuki Ohkuri, Kenzo Ohara, Yui Hirata, Kan Kishibe, Yuki Komabayashi, Seigo Ueda, Miki Takahara, Takumi Kumai, Kei Ishibashi, Akemi Kosaka, Naoko Aoki, Kensuke Oikawa, Yuji Uno, Naoko Akiyama, Masatoshi Sado, Hidehiro Takei, Esteban Celis, Yasuaki Harabuchi, Hiroya Kobayashi

Clinical Significance of TDP-43 Neuropathology in Amyotrophic Lateral Sclerosis

TDP-43 神经病理学在肌萎缩侧索硬化症中的临床意义

Matthew D Cykowski, Suzanne Z Powell, Leif E Peterson, Joan W Appel, Andreana L Rivera, Hidehiro Takei, Ellen Chang, Stanley H Appel